期刊文献+

耐药性肺结核左氧氟沙星与莫西沙星治疗的效果对比观察 被引量:9

Comparison of the Effect of Levofloxacin and Moxifloxacin in the Treatment of Drug-resistant Tuberculosis
下载PDF
导出
摘要 目的比较观察左氧氟沙星和莫西沙星在耐药性肺结核治疗中的效果。方法选择我院2015年7月—2016年7月收治的82例耐药性肺结核患者作为本次研究对象,并按照数字表法进行随机分组,每组41例。在相同基础方案治疗的前提下,Ⅰ组患者使用莫西沙星治疗、Ⅱ组患者使用左氧氟沙星治疗,比较两组患者治疗情况、痰菌转阴与空洞改善情况。结果Ⅰ组患者治疗整体有效率95.1%,比Ⅱ组患者高(P<0.05),且Ⅰ组患者在各阶段痰菌转阴率与空洞改善情况皆要好于Ⅱ组患者(P<0.05)。结论和左氧氟沙星比较,使用莫西沙星治疗耐药性肺结核的效果更好,能增加患者痰菌转阴率、更好地改善空洞情况。 Objective To observe the effect of levofloxacin and moxifloxacin in the treatment of drug-resistant tuberculosis.Methods A total of 82 patients with tuberculosis were enrolled in our hospital from July 2015 to July 2016 as subjects of this study and randomized to 41 patients in each group.In the same basic program under the premise of treatment,patients in group Ⅰ were treated with moxifloxacin,patients in Ⅱ group were treated with levofloxacin,the treatment effect,sputum negative rate and cavities improvement between two groups were compared.Results The overall effective rate of group Ⅰ was 95.1%,higher than that of group Ⅱ(P〈0.05),and the improvement negative rate of sputum and cavity in group Ⅰ were better than that in group Ⅱ(P〈0.05).Conclusion Compared with levofloxacin,the use of moxifloxacin in the treatment of drug-resistant tuberculosis is better,can increase the rate of sputum,and better improve the cavity.
作者 纪建勋
出处 《中国卫生标准管理》 2017年第26期96-98,共3页 China Health Standard Management
关键词 左氧氟沙星 莫西沙星 耐药性肺结核 levofloxacin moxifloxacin drug-resistant tuberculosis
  • 相关文献

二级参考文献65

  • 1钱建伟.用左氧氟沙星联合莫西沙星治疗社区获得性肺炎的临床效果观察[J].当代医药论丛,2014,12(5):245-246. 被引量:4
  • 2谭守勇,黎燕琼.氟喹诺酮类药物在耐多药结核病治疗中的应用[J].中国防痨杂志,2005,27(4):267-270. 被引量:30
  • 3王秀丽,曾绍艺,梁肇和,等.氟喹诺酮类药物治疗耐药肺结核的成本效果分析[J].中国医药,2012,7(z1):4-6.
  • 4王秀丽,曾绍艺,梁肇和,等.氟喹诺酮类药物治疗耐药肺结核的成本效果分析[J].中国医药,2012,7(z1):4-6.
  • 5Radhakrishna S.Contributions of the tuberculosis research centre,cbennm in the field of epidemiology of tuberculosis(a review over 50 years)[J]. Indian J Tuberc,2C12,59(2):68-77.
  • 6Tsivkovskii R, Sabet M, Tarazi Z, et al. Levotloxacin reduces inflam- matory cytokine levels in human bronchial epithelia cells: implications for aerosol MP - 376 ( levofloxacin solution for inhalation) treatment of chronic pulmonary infections [ J ]. FEMS Immunology Medical Mi- crobioloaw. 2011. 61(2)_. 141-146.
  • 7Lee SH,Seo KA,Lee YM,et al. Low serum concen- trations o{ moxi{[oxacin, prothionamide, and cy- closerine on sputum conversion in multi-drug resistant TB[J]. Yonsei Med J ,2015,56(4) :961-967.
  • 8Meng D. The curative e{{ect comparative o{ moxi- floxacin and levo{loxacin treatment o{ drug-resistant pulmonary tuberculosis [ J ]. China Rural Health, 2015,6(Total 60) :82.
  • 9Chen Z,Liang JQ, Wang J H, et al. Moxi{loxacin plus standard irst-line therapy in the treatment o{ pulmo- nary tuberculosis: A meta-analysis[J]. Tuberculosis, 2015,95 (4) . 490-496.
  • 10Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, preto- manid (PA-824),and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open- label, partly randomised trial in patients with drug- susceptible or drug-resistant pulmonary tuberculosis [J]. Lancet,2015,385 (9979) : 1738-1747.

共引文献86

同被引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部